Research & Development

Can Selective Gene Inactivation Explain Disease Variability?
Research & Development Can Selective Gene Inactivation Explain Disease Variability?

Traditionally, it is believed that each cell contains two copies of each gene, one from each parent, playing equal parts in cellular functions. This new study challenges that notion by revealing that some cells exhibit a bias and inactivate one parental gene copy over the other. This phenomenon,

New Non-Invasive Blood Test Revolutionizes Endometriosis Diagnosis
Research & Development New Non-Invasive Blood Test Revolutionizes Endometriosis Diagnosis

Endometriosis, a chronic and often debilitating condition affecting approximately 190 million women and teenage girls globally, has traditionally been diagnosed through a lengthy and invasive process. For years, women have had to endure intrusive procedures and lengthy waits before receiving a

Can CDKN2A Mutations Be Both Protective and Harmful in Esophageal Cancer?
Research & Development Can CDKN2A Mutations Be Both Protective and Harmful in Esophageal Cancer?

Recent groundbreaking research on genetic mutations in esophageal cancer has revealed surprising insights into the role of the CDKN2A gene. Traditionally seen as a driver of cancer development, this gene might also play a protective role in the early stages of esophageal cancer. This discovery

Can Tumor Organoids From Blood Samples Transform Breast Cancer Treatment?
Research & Development Can Tumor Organoids From Blood Samples Transform Breast Cancer Treatment?

A significant breakthrough by researchers from the German Cancer Research Center (DKFZ), Heidelberg Stem Cell Institute (HI-STEM), and NCT Heidelberg in addressing breast cancer metastasis has the potential to revolutionize treatment approaches. Metastases to vital organs like the liver, lungs, or

How Will the Nooyis' $1M Gift Impact Breast Cancer Research at Yale?
Research & Development How Will the Nooyis' $1M Gift Impact Breast Cancer Research at Yale?

Philanthropy plays a crucial role in advancing medical research, and the recent $1 million donation from Raj and Indra Nooyi to the Yale School of Medicine's Department of Surgery exemplifies this impact. This substantial gift has been directed to establish the Raj and Indra Nooyi Cancer Research

Takeda Advances Psoriasis Treatment with Oral TYK2 Inhibitor TAK-279
Research & Development Takeda Advances Psoriasis Treatment with Oral TYK2 Inhibitor TAK-279

Psoriasis, often misunderstood as merely a skin condition, is a complex immune-mediated disease impacting around 125 million individuals globally. This systemic condition demands comprehensive treatment strategies that go beyond addressing superficial skin symptoms. Dr. Graham Heap, Vice President

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later